Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Classification and ctDNA Monitoring in mRCC
NCT05816642Unknown
- Sponsor
- Renji Hospital
- Start
- Aug 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of sunitinib, pazopanib and axitinib in metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by Renji Hospital. Primary endpoint: Progression-Free Survival at 20 months. Status: unknown.
02
Drugs
sunitinibpazopanibaxitinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT05816642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05816642.